Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) FCF Margin (2017 - 2025)

Neurocrine Biosciences' FCF Margin history spans 15 years, with the latest figure at 48.02% for Q4 2025.

  • For Q4 2025, FCF Margin rose 481.0% year-over-year to 48.02%; the TTM value through Dec 2025 reached 27.29%, up 210.0%, while the annual FY2025 figure was 27.29%, 210.0% up from the prior year.
  • FCF Margin reached 48.02% in Q4 2025 per NBIX's latest filing, up from 31.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 646.5% in Q2 2022 to a low of 39.39% in Q4 2021.
  • Average FCF Margin over 5 years is 51.1%, with a median of 28.72% recorded in 2023.
  • Peak YoY movement for FCF Margin: surged 61227bps in 2022, then crashed -60687bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 39.39% in 2021, then surged by 178bps to 30.87% in 2022, then decreased by -10bps to 27.93% in 2023, then surged by 55bps to 43.21% in 2024, then increased by 11bps to 48.02% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's FCF Margin are 48.02% (Q4 2025), 31.46% (Q3 2025), and 13.02% (Q2 2025).